Understand · Treat · Recover

Targeted Therapy, Immunotherapy and CAR-T

Modern treatment can act on cancer pathways, specific cell markers or the immune system. Suitability depends on the exact blood cancer.

For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.

Chapter 16 of 20 · H · Treatment options

Matching a medicine to the disease

Targeted drugs interrupt selected growth or survival pathways. Examples include BCR::ABL1 inhibitors in CML and selected ALL, BTK inhibitors in certain lymphoid cancers, and drugs directed at selected AML mutations. Some require a molecular test; others are chosen using the diagnosis and clinical setting. An incidental gene change is not automatically a useful target.

Antibodies and immune treatments

Antibodies can recognize markers such as CD20 on selected B-cell cancers. Antibody-drug conjugates carry a treatment payload to a target. Bispecific antibodies bring immune cells close to cancer cells; checkpoint inhibitors release selected immune brakes and are useful in particular diseases, including some Hodgkin lymphoma settings. These mechanisms are different, so the word immunotherapy does not identify one universal treatment.

How CAR-T works

For commonly used CAR-T approaches, T cells are collected, modified to recognize a target and returned after preparatory treatment. Manufacturing and treatment planning take time; some patients need bridging treatment. CAR-T can produce prolonged remissions in selected B-cell cancers and myeloma, but it does not work for every patient or every blood cancer.

Important CAR-T and bispecific risks

Cytokine-release syndrome can cause fever, low blood pressure and breathing difficulty. Neurological toxicity can cause confusion, speech changes, marked sleepiness or seizures. These need immediate specialist assessment. Infections and prolonged low counts or impaired antibody production are additional concerns. Carry the treatment information card and follow the centre’s monitoring, travel and caregiver instructions.

Oral does not mean harmless

Targeted tablets can cause substantial toxicity and interact with other medicines, supplements or food. Follow the exact prescribed schedule and laboratory monitoring. Do not crush, share, stop or change doses independently. Report new symptoms early; a planned dose adjustment can be part of good treatment.

Access and treatment decisions

Confirm the exact indication, local availability, manufacturing or referral arrangements, and the total cost including complications and follow-up. Approval in one country does not establish availability or approval in another. Ask about reasonable alternatives and clinical trials. The newest or most expensive treatment is not automatically the best next treatment for a particular patient.

Take-home message

Choose the treatment by diagnosis, evidence and individual suitability, with a clear toxicity plan.

Common questions

Can CAR-T replace all chemotherapy?

No. It is an option for selected diseases and settings, and preparatory or bridging treatment may still be needed.

Are targeted treatments free of side effects?

No. Their risks differ from conventional chemotherapy and still require monitoring.

Sources and further reading

Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.